SCHEMBL8723629

SCHEMBL8723629

FC(F)(F)c1cccc(Oc2ccnc(Cl)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.51
ALDH1A1 P00352 2/20 0.51
POLB P06746 1/20 0.51
KDR P35968 2/20 0.45
BRAF P15056 1/20 0.45
MAPK14 Q16539 1/20 0.45
TNNI3K Q59H18 1/20 0.45
NTRK1 P04629 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
GAA P10253 1/20 0.44
RET P07949 1/20 0.43
PDGFRB P09619 1/20 0.43
KIT P10721 1/20 0.43
FLT1 P17948 1/20 0.43
FLT4 P35916 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6180609 0.83 FFAR4 (0.50) MAPTL3MBTL1ALDH1A1POLBKDR
SCHEMBL29607042 0.82 MAPT (0.65) MAPTL3MBTL1ALDH1A1POLBNTRK1
SCHEMBL8773158 0.82 MAPT (0.65) MAPTL3MBTL1ALDH1A1POLBNTRK1
SCHEMBL3457474 0.82 MAPT (0.58) MAPTL3MBTL1ALDH1A1POLBNTRK1
SCHEMBL19510904 0.81 LMNA (0.46) MAPTKDRBRAFMAPK14TNNI3K
SCHEMBL8720576 0.81 MAPT (0.48) MAPTL3MBTL1ALDH1A1POLBKDR
SCHEMBL29387718 0.81 FFAR4 (0.52) MAPTL3MBTL1ALDH1A1POLBKDR
SCHEMBL8668427 0.81 GAA (0.51) MAPTL3MBTL1ALDH1A1POLBKDR
SCHEMBL336755 0.81 FFAR4 (0.52) MAPTL3MBTL1ALDH1A1POLBKDR
SCHEMBL17609059 0.80 MAP4K4 (0.50) MAPTL3MBTL1ALDH1A1BRAFCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107567443-B Biaryl derivatives as GPR120 agonists 株式会社LG化学 2023-04-28 CN disclosed
CN-115925679-A Biaryl derivatives as GPR120 agonists 株式会社LG化学 2023-04-07 CN disclosed
EP-3239143-B1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEMICAL LTD (KR) 2023-03-22 EP disclosed
US-20220135574-A1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEM, LTD. (KR) 2022-05-05 US disclosed
US-11261186-B2 Biaryl derivative as GPR120 agonist LG CHEM. LTD. (KR) 2022-03-01 US disclosed
US-20170349594-A1 BIARYL DERIVATIVE AS GPR120 AGONIST LG CHEM, LTD. (KR) 2017-12-07 US disclosed
EP-3239143-A2 BIARYL DERIVATIVE AS GPR120 AGONIST LG Chem, Ltd. (KR) 2017-11-01 EP disclosed
EP-0700391-B1 HERBICIDAL COMPOUNDS SHELL INT RESEARCH (NL) 1998-10-21 EP disclosed
US-5759956-A PYRAZINE CARBOXAMIDE DERIVATIVES AMERICAN CYANAMID COMPANY (US) 1998-06-02 US disclosed
EP-0700391-A1 HERBICIDAL COMPOUNDS SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1996-03-13 EP disclosed
WO-1994027974-A1 HERBICIDAL COMPOUNDS SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) 1994-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135574-A1 BIARYL DERIVATIVE AS GPR120 AGONIST GPR119, GLP1R, GIPR MAPT 4515/4885L3MBTL1 2990/4885ALDH1A1 2174/4885
US-20170349594-A1 BIARYL DERIVATIVE AS GPR120 AGONIST GPR119, GLP1R, GIPR MAPT 4515/4885L3MBTL1 2990/4885ALDH1A1 2174/4885
US-11261186-B2 Biaryl derivative as GPR120 agonist GPR119, GPR88, FFAR1 MAPT 3859/4885L3MBTL1 4242/4885ALDH1A1 1152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.